Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 3
1973 3
1974 2
1975 6
1976 5
1977 4
1978 6
1979 5
1980 7
1981 4
1982 9
1983 12
1984 8
1985 14
1986 27
1987 34
1988 50
1989 61
1990 40
1991 44
1992 70
1993 49
1994 63
1995 55
1996 39
1997 37
1998 35
1999 42
2000 49
2001 63
2002 63
2003 62
2004 89
2005 84
2006 110
2007 112
2008 132
2009 162
2010 157
2011 174
2012 180
2013 178
2014 176
2015 219
2016 181
2017 227
2018 225
2019 170
2020 191
2021 202
2022 30
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

3,640 results

Results by year

Filters applied: . Clear all
Page 1
Synthetic cytokine circuits that drive T cells into immune-excluded tumors.
Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, Purl M, Lee J, Yee JL, Yu W, Li AW, Garcia KC, El-Samad H, Roybal KT, Spitzer MH, Lim WA. Allen GM, et al. Science. 2022 Dec 16;378(6625):eaba1624. doi: 10.1126/science.aba1624. Epub 2022 Dec 16. Science. 2022. PMID: 36520915 Free PMC article.
The future of engineered immune cell therapies.
Irvine DJ, Maus MV, Mooney DJ, Wong WW. Irvine DJ, et al. Science. 2022 Nov 25;378(6622):853-858. doi: 10.1126/science.abq6990. Epub 2022 Nov 24. Science. 2022. PMID: 36423279 Free PMC article. Review.
Natural killer cell therapies.
Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Vivier E, et al. Nature. 2024 Feb;626(8000):727-736. doi: 10.1038/s41586-023-06945-1. Epub 2024 Feb 21. Nature. 2024. PMID: 38383621 Review.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Liu E, et al. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. Stadtmauer EA, et al. Science. 2020 Feb 28;367(6481):eaba7365. doi: 10.1126/science.aba7365. Epub 2020 Feb 6. Science. 2020. PMID: 32029687 Clinical Trial.
Next-generation regulatory T cell therapy.
Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Ferreira LMR, et al. Nat Rev Drug Discov. 2019 Oct;18(10):749-769. doi: 10.1038/s41573-019-0041-4. Epub 2019 Sep 20. Nat Rev Drug Discov. 2019. PMID: 31541224 Free PMC article. Review.
3,640 results